mass spectrometry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
The identification of suitable matrix compounds is determined to some extent by trial and error, but they are based on some specific molecular design considerations. They are of a fairly low molecular weight (to allow easy vaporization), but are large enough (with a low enough vapor pressure) not to evaporate during sample preparation or while standing in the mass spectrometer. They are often acidic, therefore act as a proton source to encourage ionization of the analyte. Basic matrices have also been reported. They have a strong optical absorption in either the UV or IR range, so that they rapidly and efficiently absorb the laser irradiation. This efficiency is commonly associated with chemical structures incorporating several conjugated double bonds, as seen in the structure of cinnamic acid. They are functionalized with polar groups, allowing their use in aqueous solutions. They typically contain a chromophore. The matrix solution is mixed with the analyte (e.g. protein-sample). A mixture of water and organic solvent allows both hydrophobic and water-soluble (hydrophilic) molecules to dissolve into the solution. This solution is spotted onto a MALDI plate (usually a metal plate designed for this purpose). The solvents vaporize, leaving only the recrystallized matrix, but now with analyte molecules embedded into MALDI crystals. The matrix and the analyte are said to be co-crystallized. Co-crystallization is a key issue in selecting a proper matrix to obtain a good quality mass spectrum of the analyte of interest.
==== Human rights abuses and corruption ==== Building off the Global Magnitsky Human Rights Accountability Act, named after Sergei Magnitsky who died in Russian custody after uncovering corruption, the U.S. can enact sanctions against any individual or entity worldwide who it says engages in severe human rights abuses and corruption that degrade the rule of law, perpetuate violent conflicts, and facilitate the activities of dangerous persons. The following jurisdictions are frequently targeted by U.S. sanctions related to human rights abuses but are not specifically targeted under a country-specific sanctions program:
The Association for Laboratory Medicine (previously the Association for Clinical Biochemistry and Laboratory Medicine) is a United Kingdom-based learned society dedicated to the practice and promotion of laboratory medicine which consists of the clinical biochemistry, immunology and microbiology professions. It was founded on 28 March 1953 at the inaugural meeting attended by 75 members at the Hammersmith Hospital in London, and its official journal is the Annals of Clinical Biochemistry. The association is a full, national society member of the International Federation of Clinical Chemistry and Laboratory Medicine IFCC as well as a full member of the regional European Federation of Clinical Chemistry and Laboratory Medicine. Its qualifying members are automatically members of the certificated trade union called Federation of Clinical Scientists (FCS), which represents the interests of clinical scientists. Some members who meet the eligibility criteria are enrolled to the register of European Specialists in Laboratory Medicine (EuSpLM).
=== Efforts to reduce recreational use in the US === In 2011, the Obama administration released a white paper describing the administration's plan to deal with the opioid crisis. The administration's concerns about addiction and accidental overdosing have been echoed by numerous other medical and government advisory groups around the world. As of 2015, prescription drug monitoring programs exist in every state except for Missouri. These programs allow pharmacists and prescribers to access patients' prescription histories in order to identify suspicious use. However, a survey of US physicians published in 2015 found that only 53% of doctors used these programs, while 22% were not aware that the programs were available to them. The Centers for Disease Control and Prevention (CDC) was tasked with establishing and publishing a new guideline, and was heavily lobbied. In 2016, the CDC published its Guideline for Prescribing Opioids for Chronic Pain, recommending that opioids only be used when benefits for pain and function are expected to outweigh risks, and then used at the lowest effective dosage, with avoidance of concurrent opioid and benzodiazepine use whenever possible. Research suggests that the prescription of high doses of opioids related to chronic opioid therapy (COT) can at times be prevented through state legislative guidelines and efforts by health plans that devote resources and establish shared expectations for reducing higher doses. On 10 August 2017, Donald Trump declared the opioid crisis a (non-FEMA) national public health emergency.
Sources: en.wikipedia.org
=== Health experiences === Trans people report multiple negative experiences in health care encounters, contributing to stigmatization of their gender identity. A systematic review conducted by researchers at James Cook University reported that 75.3% of respondents have negative experiences during physician visits when seeking gender identity-based care. Transgender patients also face obstacles to accessing health care that result in adverse effects on their health and quality of life. These include unsafe public spaces, lack of knowledgeable health care professionals, discrimination while accessing care, lack of institutional support, long distances to access treatment, and denial of health care services and health insurance benefits. These often result in trans people avoiding or delaying health care. Trans patients may also avoid treatment as a result of their gender identities being treated as psychological illnesses, or because they fear "discrimination and suboptimal or inappropriate care" as a result of disclosing their gender identities. For instance, after a transgender man seeking medical care in the emergency department was verbally assaulted by the hospital employees, who repeatedly referred to him as a woman, he left the hospital premises before receiving the care he needed. According to a systematic review conducted by Hermaszewska and colleagues, "some transgender people are forced to migrate to countries that offer them better legal protection and wider social acceptance". Others may self-prescribe medication such as gender-affirming hormone therapy.
== Career == In 2001, Nigam founded the Swansea University Maggot Research Group, of which she is a director. The group focuses on therapeutic applications of the medicinal maggot Lucilia sericata. She then became an associate professor at Swansea University. In 2018, Nigam was promoted to professor which included a move from the research to the innovation and engagement strand. Nigam fulfills many roles outside of her permanent academic position. In 2007, she became a member of the Welsh Wound Network group, an enterprise which aims to support the clinical development of wound healing science. In April 2014, she was an elected participant of the Welsh Crucible Programme. Nigam is an elected Fellow of the Royal Entomological Society (FRES).
Placing a wedge in the felling cut can prevent a sitback from pinching the saw. Freeing: Working a badly fallen tree that may have become trapped in other trees. Working out maximum tension locations to decide the safest way to release tension, and a winch may be needed in complicated situations. To avoid cutting straight through a tree in tension, one or two cuts at the tension point of sufficient depth to reduce tension may be necessary. After tension releases, cuts are made outside the bend. Limbing: Cutting the branches off the log. The operator must be able to properly reach the cut to avoid kickback. Bucking: Cross-cutting the felled log into sections. Setup is made to avoid binding the chainsaw within the changing log tensions and compressions. Safe bucking is started at the log high-side and then sections worked offside, toward the butt end. The offside log falls and allows for gravity to help prevent binds. The log's kerf movement while cutting can help to indicate binds. Additional equipment (lifts, bars, wedges, and winches) and special cutting techniques can help prevent binds. Binds: This is when the chainsaw is at risk or is stuck in the log compression. A log bound chainsaw is unsafe and must be carefully removed to prevent equipment damage. Top bind – The tension area on log bottom, compression on top. Bottom bind – The tension area on log top, compression on bottom. Side bind – Sideways pressure exerted on the log. End bind – Weight compresses the log's entire cross-section.
Sources: en.wikipedia.org
=== John B. Fenn Award for a Distinguished Contribution in Mass Spectrometry (since 1990) === 2024 Jennifer Brodbelt 2023 Carol Vivien Robinson 2017 Catherine E. Costello 2012 Catherine C. Fenselau 2009 Vicki H. Wysocki
=== Professional directories === The IIR publishes two professional directories: a Laboratory Directory, which lists more than 300 laboratories in 55 countries; an Expertise Directory, which lists over 300 international experts in the refrigeration sector.
== Awards == 1973 - 25th Annual Institute Lecturer, American Institute of Chemical Engineers 1975 - Food, Pharmaceutical and Bioengineering Division Award, American Institute of Chemical Engineers 1976 - William H. Walker Award, American Institute of Chemical Engineers 1978 - George Westinghouse Award, American Society for Engineering Education 1981 - Member, National Academy of Engineering 1983 - Fellow, American Institute of Chemical Engineers 1988 - Ninth Centennial Lecturer in Chemical Engineering, University of Bologna 1990 - Award for Excellence in Drying Research, International Drying Symposium 1990 - Mac Pruitt Award, Council for Chemical Research 1990 - Warren K. Lewis Award, American Institute of Chemical Engineers 1992 - Clarence G. Gerhold Award, Separations Division of AIChE 1993 - Fellow, American Association for the Advancement of Science 1993 - Centennial Medallion, American Society for Engineering Education 1997 - Award in Separations Science and Technology, American Chemical Society 1998 - Outstanding Alumnus, Yale Science and Engineering Association, Yale University 1998 - The Electrochemical Society Lecture, The Electrochemical Society 2009 - 100 Chemical Engineers of the Modern Era, Amer. Institute of Chemical Engineers 2018 - Clark Kerr Award, Academic Senate, University of California, Berkeley
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.